Approvals· May 26, 2026 · 8 min read
Novel FDA drug approvals Q1-Q2 2026: the fifteen drugs and their formulary implications
By Ran Chen#FDA Approval#Novel Drug Approvals#GLP-1
Topic
PROTAC
PROteolysis TArgeting Chimeras, heterobifunctional protein degraders, targeted protein degradation, and the access implications of this new modality.
Pricing & Access· May 26, 2026 · 7 min read
Veppanu (vepdegestrant) coverage guide: the first PROTAC degrader for ER+/HER2− breast cancer
By Ran Chen#PROTAC#Breast Cancer#Companion Diagnostic